Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine

British Journal of Cancer
P L de SouzaC E Myers

Abstract

Cytoplasmic phospholipase A2 (PLA2) is known to be phosphorylated and activated by MAP kinase (Lin et al 1993, Cell 72: 269-278), an important downstream component of signal transduction, whereas paclitaxel has been shown to inhibit isoprenylation of ras proteins (Danesi et al 1995, Mol Pharmacol 47: 1106-1111). Given that quinacrine (Q), a PLA2 inhibitor, and paclitaxel (P) might act at different sites in the cell signalling pathway, our aim was to test whether they were synergistic in combination against prostate cancer cells. Cell viability of PC-3, PC-3M and DU145 cells in 96 - well plates was assessed 96 h after drugs were added concurrently. Using Chou analysis, we demonstrated synergy for the combination against all three cell lines. Further, synergy was present under both conservative (mutually non-exclusive) and non-conservative (mutually exclusive) models. Studies in the nude mouse xenograft model support the finding of synergy in vitro. In DU145-bearing mice, Q (50 mg kg(-1)) and P (0.5 mg kg(-1)) given daily for 12 consecutive days, either concurrently or sequentially, was more effective than either drug alone, at twice the dose intensity. In an enzyme-linked immunosorbent (ELISA) apoptosis assay, arachidonic acid w...Continue Reading

Citations

Jul 23, 2016·Nature Reviews. Drug Discovery·Timothy A YapJohann S de Bono
May 8, 2001·Archives of Pharmacal Research·A A FasanmadeA N Kong
Feb 12, 2009·British Journal of Cancer·R A C McPhersonP L de Souza
Nov 3, 2011·Journal of Signal Transduction·Gonzalo Rodríguez-BerrigueteMar Royuela
May 6, 2011·International Journal of Cancer. Journal International Du Cancer·Ranjan PreetChanakya Nath Kundu
Jun 2, 2005·International Journal of Cancer. Journal International Du Cancer·Venkata S SabbisettiGirish V Shah
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xi ZhengAllan H Conney
Sep 29, 2019·Seminars in Cancer Biology·Derek B OienViji Shridhar
May 27, 2017·Gynecologic Oncology·Eleftheria KalogeraViji Shridhar
Nov 25, 1998·Biochemical Pharmacology·K G Waddick, F M Uckun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis